We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stay Ahead of the Game With Moderna (MRNA) Q3 Earnings: Wall Street's Insights on Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that Moderna (MRNA - Free Report) will report quarterly loss of -$2.15 per share in its upcoming release, pointing to a year-over-year decline of 7266.7%. It is anticipated that revenues will amount to $860.07 million, exhibiting a decrease of 53.8% compared to the year-ago quarter.
The current level reflects a downward revision of 5.8% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Moderna metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus among analysts is that 'Revenue- Net Product sales' will reach $835.12 million. The estimate suggests a change of -54.1% year over year.
The consensus estimate for 'Revenue- Other revenue' stands at $25.19 million. The estimate points to a change of -40% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenue- Other revenue- Grant revenue' of $5.56 million. The estimate indicates a change of -20.6% from the prior-year quarter.
It is projected by analysts that the 'Product sales- Rest of world' will reach $196.36 million. The estimate suggests a change of -39.4% year over year.
Analysts expect 'Product sales- United States' to come in at $499.39 million. The estimate suggests a change of -58.9% year over year.
Moderna shares have witnessed a change of -4.7% in the past month, in contrast to the Zacks S&P 500 composite's +2.4% move. With a Zacks Rank #3 (Hold), MRNA is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Stay Ahead of the Game With Moderna (MRNA) Q3 Earnings: Wall Street's Insights on Key Metrics
Wall Street analysts forecast that Moderna (MRNA - Free Report) will report quarterly loss of -$2.15 per share in its upcoming release, pointing to a year-over-year decline of 7266.7%. It is anticipated that revenues will amount to $860.07 million, exhibiting a decrease of 53.8% compared to the year-ago quarter.
The current level reflects a downward revision of 5.8% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Moderna metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus among analysts is that 'Revenue- Net Product sales' will reach $835.12 million. The estimate suggests a change of -54.1% year over year.
The consensus estimate for 'Revenue- Other revenue' stands at $25.19 million. The estimate points to a change of -40% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenue- Other revenue- Grant revenue' of $5.56 million. The estimate indicates a change of -20.6% from the prior-year quarter.
It is projected by analysts that the 'Product sales- Rest of world' will reach $196.36 million. The estimate suggests a change of -39.4% year over year.
Analysts expect 'Product sales- United States' to come in at $499.39 million. The estimate suggests a change of -58.9% year over year.
View all Key Company Metrics for Moderna here>>>Moderna shares have witnessed a change of -4.7% in the past month, in contrast to the Zacks S&P 500 composite's +2.4% move. With a Zacks Rank #3 (Hold), MRNA is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .